Tempus AI (TEM) said Wednesday it entered a multi-year collaboration with Genialis to advance the development and validation of RNA-based biomarker algorithms for cancer treatment.
Financial details weren't disclosed.
Genialis will leverage Tempus' multimodal dataset to validate its AI foundation model, which is based on data from around 1 million RNA-sequencing samples.
Through this partnership, Genialis can now use Tempus' multimodal dataset and analytics platform, Lens, to access de-identified patient records and tools for signature validation, aiding in the market launch of its clinical algorithms.
Tempus, in turn, gains the right to evaluate and potentially license these algorithms for use in its xR platform, the company said.
Shares of Tempus were down 2.1% in recent trading.
Price: 38.06, Change: -0.81, Percent Change: -2.10
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。